Ainos (NASDAQ:AIMD) Issues Earnings Results

Ainos (NASDAQ:AIMD) posted its quarterly earnings data on Monday. The company reported ($0.62) earnings per share for the quarter, FiscalAI reports. Ainos had a negative return on equity of 186.12% and a negative net margin of 11,912.10%.The company had revenue of $0.15 million for the quarter.

Ainos Stock Performance

NASDAQ:AIMD opened at $1.41 on Wednesday. The firm’s fifty day simple moving average is $1.85 and its 200-day simple moving average is $1.73. The company has a quick ratio of 0.50, a current ratio of 0.55 and a debt-to-equity ratio of 1.58. The stock has a market cap of $12.01 million, a PE ratio of -0.49 and a beta of 2.46. Ainos has a fifty-two week low of $1.26 and a fifty-two week high of $4.50.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded Ainos from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, May 26th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell”.

Insider Activity at Ainos

In other Ainos news, Director Chun-Jung Tsai sold 27,718 shares of the company’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $1.87, for a total transaction of $51,832.66. Following the transaction, the director directly owned 658,199 shares in the company, valued at approximately $1,230,832.13. This represents a 4.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, major shareholder Carbon Nano Technology Taiwan sold 41,000 shares of the stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $2.36, for a total transaction of $96,760.00. Following the completion of the transaction, the insider directly owned 948,925 shares of the company’s stock, valued at approximately $2,239,463. This trade represents a 4.14% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders purchased 7,500 shares of company stock worth $15,435 and sold 179,788 shares worth $359,247. Company insiders own 9.79% of the company’s stock.

Hedge Funds Weigh In On Ainos

Several hedge funds have recently bought and sold shares of AIMD. Mariner LLC acquired a new position in Ainos during the fourth quarter worth $37,000. Two Sigma Investments LP purchased a new position in shares of Ainos in the third quarter valued at $80,000. DRW Securities LLC increased its position in shares of Ainos by 272.6% in the fourth quarter. DRW Securities LLC now owns 66,211 shares of the company’s stock valued at $109,000 after buying an additional 48,439 shares in the last quarter. Finally, Renaissance Technologies LLC increased its position in shares of Ainos by 13.1% in the fourth quarter. Renaissance Technologies LLC now owns 66,300 shares of the company’s stock valued at $109,000 after buying an additional 7,700 shares in the last quarter.

Ainos Company Profile

Ainos, Inc (NASDAQ: AIMD) is a clinical?stage biopharmaceutical company dedicated to developing inhalation therapies for patients with chronic pulmonary disorders. The company’s proprietary platform centers on a dry powder inhalation technology designed to deliver therapeutic agents directly to the lungs, potentially improving drug distribution and reducing systemic side effects compared to traditional oral or intravenous formulations.

The lead product candidate, AI?401, is an inhaled formulation of ibuprofen in a dry powder format.